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Several studies have suggested that viral oncogenesis is one of the etiologic factors of breast cancer, while others are provocative,
however, their association remains controversial. The purpose of this study was to investigate whether the human papillomavirus
(HPV) DNA is present in the blood and tissue samples of breast cancer patients in Hong Kong. A total of 102 patients with breast
tumour tissues and adjacent normal tissues were available and recruited unselectively. Both DNA and RNA were extracted from
those samples, and real-time quantitative PCR was performed to detect HPV-16, with 18 sequences targeting the E6 and L1 regions.
Results showed that HPV DNA sequences were absent in all the blood and breast tissues. These data argue against the role of
oncogenic HPV in the pathogenesis of breast cancer. Additional lines of evidence need to be obtained in order to assess the
possibility of breast cancer prevention using HPV vaccines.
1. Introduction
The incidence of breast cancer in Hong Kong is 1 in 20.
Although this is lower than that ofWestern population, breast
cancer is still the most common cancer in Chinese women,
and the incidence is rising. Despite decades of research, the
etiologic factor(s) for human breast cancer remains unclear.
Many studies have identified risk factors such as age, diet, hor-
monal balance, and genetic predisposition, but a clear under-
lying cause for the disease has not been established. Emerging
evidence suggests that breast cancer most likely is a multifac-
torial disease consisting of many different causes and factors
[1].Thus, the possibility that a virus is etiologically involved in
breast cancer has not been eliminated.
Human papilloma virus (HPV) is widely known to be a
major instigator for both cervical cancer [2] and a subset of
cancers of the head and neck [3]. However, the involvement
of the virus in breast cancer remains inconclusive. Previous
reports have shown that HPV DNA was detected in breast
cancer specimens fromdiverse populations around theworld.
The prevalence of HPV positive breast cancer in these studies
was reported to vary from 4% to 86% [4]. Although further
clarification is required, there have also been promising
results in the correlation between breast cancer and HPV [5].
In 2009, Heng et al. [6] substantiated the presence of DNA
pertaining to high-risk HPV subtypes 16 and 18 in the spec-
imens of breast cancer cells. Furthermore, Heng et al. found
that the oncogenic properties of these HPV-associated breast
cancers were comparable to HPV-associated cervical cancer.
This evidence suggested a relationship between HPV-16 and
HPV-18 and breast cancer and also highlighted that the
pathogenesis of cervical cancer caused by HPV-16 and HPV-
18 may share a similar mechanism to cause breast cancer.The
latter theory has been further exemplified with the discovery
of koilocytosis (a condition where cellular alteration leads to
an appearance of haloed nuclei) in breast cancer cells. These
cellular changes have been well documented in HPV-associ-
ated cervical cancer cells [2], and the presence of koilocytes
in breast cancer provides additional evidence that HPV may
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play a causal role instead of being merely a passenger in the
pathogenesis of the disease [7].
As the aetiology of most breast cancers remains unclear,
and that ethnic differences are also increasingly coming to
play a role to complicate the multifactorial causes of breast
cancer, it is important to verify these observations in Hong
Kong breast cancer populations which mainly comprise of
Asian ethnic background, and the majority of them are Chi-
nese.TheHPVdetection rate in breast cancer is 20%, which is
consistent with previous publications reporting the presence
of HPV in breast cancer worldwide with a prevalence ranging
from4 to 86% [4]. In the present study,we used our developed
assays to evaluate the current prevalence ofHPV sequences in
breast tumor and normal breast tissue specimens from Hong
Kongpatients.This study is enormously beneficial to our local
community.The increased use of HPV vaccination to prevent
cervical cancer is already in place. If it is proven that HPV
infection does play an important role in the development of
breast cancer, HPV vaccinations can also be implemented in
the prevention strategies for breast cancer.
2. Materials and Methods
2.1. Study Population. Over 150 Chinese women, the age
range is from 38 to 72, with breast cancer have been recruited
with informed consent through the Hong Kong Hereditary
Breast Cancer Family Registry (Hong Kong Registry), Queen
Mary Hospital, and other hospitals in Hong Kong. Preop-
erative blood samples, corresponding breast tumor tissues,
and their surrounding noncancerous breast tissues from this
patient cohort were collected if available. Samples were col-
lected under protocols approved by the Institutional Review
Boards (IRB) of the University of Hong Kong. Although 150
breast cancer patients were recruited, only 102 patients had
both peripheral blood and paired adjacent normal/tumor tis-
sues for qPCR assays.
2.2. Detection of HPV Sequences by Real-Time Quantitative
PCR and RT-PCR. Detection of HPV sequences were per-
formed using LNA-based probe qPCR and SYBR green
qPCR. Both RNA and DNA were extracted from tumors,
their corresponding normal breast tissues, and blood sam-
ples using RNeasy and QIAamp DNA mini extraction kit
(Qiagen), respectively. DNA and RNA qualities were assessed
by NanoDrop spectrophotometer. Amplifications were con-
ducted together with internal reference sequences of the 𝛽-
globin gene (for DNAdetection) and 𝛽-actin (for RNAdetec-
tion). qPCR and qRT-PCR assays were used for HPV DNA
and RNA detection, respectively. For HPV RNA detection,
100 ng (from blood) and 50 ng (from tissues) of RNA were
reverse transcribed to cDNA using reverse transcription kit
(Qiagen). For HPV DNA detection, 20 ng (from blood) and
10 ng (from tissues) of DNAwere used. Single target real-time
qPCR and qRT-PCR are performed using LC480Q Probe
Master kit (Roche) in Roche LC480 (Roche). PCR primers
targeting both L1 and E regions of HPV-16 and HPV-18 have
been used for this project. Each sample was run in duplicates
for analysis.
2.3. HPVSubtyping byDNASequencing. To confirm the pres-
ence of HPV viral sequences and rule out those amplification
of nonspecific sequences, the amplified products of the posi-
tive breast cancer sampleswould be sequenced. PCRproducts
were purified from agarose gels using PCR Clean-Up Purifi-
cation kit (Qiagen) and sequenced on an ABI PRISM 3100
(Applied Biosystems).
3. Results and Discussion
The mean age of breast cancer patients was 52 years with the
range from 38 to 72 years. No patient presented a history
of HPV infection of cervical cancer. In this study, 102 breast
cancer patients recruited: 94 had invasive ductal carcinoma
(IDC), and 8hadductal carcinoma in situ (DCIS).The follow-
ing is the distribution of IDC patients with TNM stage: stage
1, 𝑛 = 28; stage 2, 𝑛 = 55; stage 3, 𝑛 = 8; and stage 4, 𝑛 = 3. Our
results showed that all tested samples were negative for the
presence of both E6 and L1 region sequences of both HPV-16
and HPV-18. In order to examine whether other HPV sub-
types were present, we performed qPCR with universal
primer set targeting the L1 common region. Interestingly, we
could not detect any amplification in our samples, indicating
the absence of HPV sequences in breast cancer samples.
Our results seemed to be contradictingwith other studies,
reporting HPV positivity in breast cancer. However, the
results observed from these papers are not coherent. The
inconsistency may be due to the following: (1) the study pop-
ulations were not from the same origin; (2) high risk or low
risk HPV was sometimes detected and is not the same in all
cases; (3) HPVpositivity frequency varies among individuals.
Positivity of certainHPV subtypewas also detected in normal
samples without breast cancer [8–14].
On the other hand, several studies failed to detect HPV
positivity in breast carcinoma. Wrede et al. [15] studied HPV
subtypes 6b, 11, 13, 16, 18, 30, 31, 32, 33, 45, and 51 in 95 women
with breast cancer without detecting any of the subtypes.
Bratthauer et al. [16] researched the HPV subtypes 6, 11, 16,
and 18 in 13 IDC, 15 papillomas, and 15 papillary carcinomas
cases, and there was no evidence of HPV infection. Czer-
wenka et al. [17] also showed no association of HPV in 20
cases of Paget’s disease. Furthermore, Lindel et al. [18] used six
different primers, including a total of 40 subtypes 16, 18, 31, 33,
and 45 in 81 Swiss women cases with breast cancer, and no
positivity of HPV was detected. De Cremoux et al. [19] stud-
ied the prevalence of subtypes of high (16, 18, 33, and 45) and
low risks (6, 11) in 50 breast cancers in women in France by
PCRwith the general primer GP5+/GP6+; none of these sub-
types were detected in both cases.
This may be due to the lack of standardized technique to
detect the presence of HPV, since there are different types of
primers for different HPV subtypes. False negatives and false
positives may occur when PCR overestimates the association
between HPV and breast cancer because it cannot indicate
which types of cells the virus has infected. Contamination
while handling the sample may be partially responsible for
the high frequencies of HPV positivity that were reported in
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several papers. Other risk factors might affect the outcome
of the results. For example, studies have shown that women
under the age of 25 have a higher prevalence of HPV
positivity detectionwith a linear decrease rate as age increases
[20]. Storage of specimens may affect the result since some
researchers found that positive specimens became negative
after being frozen at −70∘C for 3 months [21]. Demographic
features and genetic backgrounds may contribute to the
geographic difference and HPV infection in breast cancer. To
conclude, our results are consistent with the null or limited
proportion of HPV sequences explored from breast cancer
patient samples.
A definitive relationship between human breast cancer
and HPV infection has not been determined in Hong Kong
breast cancer patients. It seems unlikely that high-risk genital
HPV plays a role in breast oncogenesis. However, we cannot
exclude the possibility that HPV infection may cause breast
cancer in other areas or in other races and HPV itself is still
a pathogenic virus which causes other different kinds of can-
cers, in particular, cervical cancer.Therefore,more studies are
essential to proof or exclude the possibility of HPV being an
etiological risk factor for breast cancer.
4. Conclusions
A total of 102 patients with breast normal and tumor tissues
were used unselectively. Both DNA and RNA were extracted
from those samples and real-time quantitative PCR was per-
formed to detectHPV-16 andHPV-18 sequences targeting the
E6 and L1 regions. Results showed that HPV DNA sequences
were absent in all the blood and breast tissues samples. These
data did not show the presence of oncogenic HPV in the
breast cancer tissues. Additional lines of evidence need to be
obtained in order to assess the possibility of breast cancer
prevention using HPV vaccines.
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